Back to Search
Start Over
DPI-3290 [(+)-3-((alpha-R)-alpha-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-hydroxybenzyl)-N-(3-fluorophenyl)-N-methylbenzamide]. I. A mixed opioid agonist with potent antinociceptive activity.
- Source :
-
The Journal of pharmacology and experimental therapeutics [J Pharmacol Exp Ther] 2003 Dec; Vol. 307 (3), pp. 1221-6. Date of Electronic Publication: 2003 Oct 08. - Publication Year :
- 2003
-
Abstract
- Compound (+)-3-((alpha-R)-alpha-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-hydroxybenzyl)-N-(3-fluorophenyl)-N-methylbenzamide (DPI-3290), is one of a series of novel centrally acting agents with potent antinociceptive activity that binds specifically and with high affinity to opioid receptors. In saturation equilibrium binding studies performed at 25 degrees C using membranes from rat brain or guinea pig cerebellum, the Ki values measured for DPI-3290 at delta-, mu-, and kappa-opioid receptors were 0.18 +/- 0.02, 0.46 +/- 0.05, and 0.62 +/- 0.09 nM, respectively. In vas deferens isolated from laboratory mice, DPI-3290 decreased electrically induced tension development in a concentration-dependent manner with corresponding IC50 values of 1.0 +/- 0.3, 6.2 +/- 2.0, and 25.0 +/- 3.3 nM at delta-, mu-, and kappa-receptors, respectively. The activity of DPI-3290 in isolated vas deferens tissue was approximately 20,000, 175.8, and 1500 times more efficacious than morphine, and 492, 2.5, and 35 times more efficacious than fentanyl at delta-, mu-, and kappa-receptors, respectively. In ileal strips isolated from guinea pigs, DPI-3290 inhibited tension development with a corresponding IC50 value of 3.4 +/- 1.6 nM at mu-opioid receptors and 6.7 +/- 1.6 nM at kappa-opioid receptors. Intravenous administration of 0.05 +/- 0.007 mg/kg DPI-3290 produced a 50% antinociceptive response in rats. The antinociceptive properties of DPI-3290 were blocked by naloxone (0.5 mg/kg s.c.). Compared with morphine, this study demonstrated that DPI-3290 is more potent and elicited a similar magnitude of antinociceptive activity in the rat, actions mediated by its mixed opioid receptor agonist activity. The marked antinociceptive activity of DPI-3290 will likely provide a means for relieving severe pain in patients that require analgesic treatment.
- Subjects :
- Animals
Benzamides antagonists & inhibitors
Benzeneacetamides antagonists & inhibitors
Benzeneacetamides pharmacology
Binding, Competitive drug effects
Blood Gas Analysis
Brain Chemistry
Enkephalin, Ala(2)-MePhe(4)-Gly(5)- antagonists & inhibitors
Enkephalin, Ala(2)-MePhe(4)-Gly(5)- pharmacology
Enkephalin, D-Penicillamine (2,5)- antagonists & inhibitors
Enkephalin, D-Penicillamine (2,5)- pharmacology
Guinea Pigs
Ileum drug effects
Male
Muscle, Smooth drug effects
Narcotic Antagonists pharmacology
Pain Measurement drug effects
Piperazines antagonists & inhibitors
Pyrrolidines antagonists & inhibitors
Pyrrolidines pharmacology
Radioligand Assay
Rats
Rats, Sprague-Dawley
Receptors, Opioid, delta drug effects
Receptors, Opioid, delta metabolism
Receptors, Opioid, kappa drug effects
Receptors, Opioid, kappa metabolism
Receptors, Opioid, mu drug effects
Receptors, Opioid, mu metabolism
Stereoisomerism
Vas Deferens drug effects
Analgesics pharmacology
Benzamides pharmacology
Narcotics agonists
Piperazines pharmacology
Subjects
Details
- Language :
- English
- ISSN :
- 0022-3565
- Volume :
- 307
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- The Journal of pharmacology and experimental therapeutics
- Publication Type :
- Academic Journal
- Accession number :
- 14534368
- Full Text :
- https://doi.org/10.1124/jpet.103.054361